Evidence map›Paper›PMID 24755629›Full record

ArticlePloS one2014

Development of a multiplex autoantibody test for detection of lung cancer.

Jing Jia, Wenzhe Wang, Wen Meng, Mingjian Ding, Shenglin Ma, Xiaoju Wang

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Observational
  9. Article
  10. Article
  11. Identification of miRNAs as non-invasive biomarkers for early diagnosis of lung cancers.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Long-lived engineering of glycans to direct stem cell fate.Angewandte Chemie (International ed. in English) · 2015
    Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jing JiaCenter for Molecular Medicine, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang, P. R. China.
Wenzhe WangCenter for Molecular Medicine, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang, P. R. China.
Wen MengHangzhou First People's Hospital, Hangzhou, Zhejiang, P. R. China.
Mingjian DingCenter for Molecular Medicine, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang, P. R. China.
Shenglin MaInstitute of Lung Cancer, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang, P. R. China; Hangzhou First People's Hospital, Hangzhou, Zhejiang, P. R. China.
Xiaoju WangCenter for Molecular Medicine, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang, P. R. China; Institute of Lung Cancer, Zhejiang Academy of Medical Sciences, Hangzhou, Zhejiang, P. R. China.
Zhejiang Academy of Medical Sciences · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the leading cause of cancer-related deaths for both men and women. Early diagnosis of lung cancer has a 5-year survival rate of 48.8%, however, nearly 35% of stage I patients relapses after surgical resection, thus portending a poor prognosis. Therefore, detecting lung cancer in early stage and further identifying the high-risk patients would allow the opportunity to provide adjuvant therapy and possibly increase survival. There is considerable evidence that the immune system produces an autoantibody response to neoplastic cells. The detection of such autoantibodies has been shown to have diagnostic and prognostic value. Here we took advantage of the high-throughput Luminex technique to multiplex a total of 14 tumor-associated autoantigens to detect the autoantibody from the patients sera. The 14 antigens were expressed by in vitro transcription/translation system with HaloTag at N-terminus. The fusion proteins were then covalently immobilized onto the Luminex microspheres conjugated by the halo-link ligand, thus eliminating the protein purification procedure. Sera samples from cancer patients and healthy controls were interacted with the microsphere-antigen complex to measure the autoantibodies. We have developed a quick multiplex detection system for measuring autoantibody signature from patient sera with minimal cross-reaction. A panel of seven autoantibody biomarkers has generated an AUC>80% in distinguishing the lung cancers from healthy controls. This study is the first report by combining Luminex platform and HaloTag technology to detect humoral immune response in cancer patients. Due to the flexibility of the Luminex technology, this approach can be applied to others conditions such as infectious, neurological, and metabolic diseases. One can envision that this multiplex Luminex system as well as the panel of seven biomarkers could be used to screen the high-risk population with subsequent CT test based on the blood test result.

Indexed as

AdultAgedAutoantibodiesCase-Control StudiesCross ReactionsEarly Detection of CancerEnzyme-Linked Immunosorbent AssayFemaleHumansLigandsLung NeoplasmsMaleMiddle AgedModels, BiologicalReproducibility of ResultsROC CurveAutoantibodiesLigands

Identifiers

PMID24755629
PMCPMC3995760
OpenAlexW2091934664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.